EPA:EAPI - FR0014008VX5 - Common Stock
The current stock price of EAPI.PA is 2.962 EUR. In the past month the price decreased by -8.45%. In the past year, price decreased by -33.95%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY.DE | ELI LILLY & CO | 46.8 | 611.22B | ||
1LLY.MI | ELI LILLY & CO | 46.36 | 605.55B | ||
ZEG.DE | ASTRAZENECA PLC | 18.3 | 427.71B | ||
1JNJ.MI | JOHNSON & JOHNSON | 17.79 | 365.97B | ||
JNJ.DE | JOHNSON & JOHNSON | 17.7 | 364.09B | ||
RHO.DE | ROCHE HOLDING AG-BR | 14.23 | 242.45B | ||
NOT.DE | NOVARTIS AG-REG | 14.43 | 208.61B | ||
NOV.DE | NOVO NORDISK A/S-B | 13.8 | 204.80B | ||
SAN.PA | SANOFI | 10.69 | 196.92B | ||
SNW.DE | SANOFI | 10.64 | 195.90B | ||
1SAN.MI | SANOFI | 10.61 | 195.46B | ||
6MK.DE | MERCK & CO. INC. | 10.93 | 179.59B |
EUROAPI SA engages in manufacturing and supply of active pharmaceutical ingredient solutions for healthcare companies. The company is headquartered in Paris, Ile-De-France and currently employs 3,428 full-time employees. The company went IPO on 2022-05-06. The firm is engaged in the development, manufacture and supply of active-ingredient solutions to its healthcare partners. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates (morphine, codeine, thebaine, etc. ), analgesics, etc. The firm also provides technologies and develops molecules through it’s Contract Development and Manufacturing Organization (CDMO). It’s CDMO services include Tides, Prostaglandins, Particle Engineering, Microbial Fermentation, Small Molecules Synthesis, Steroids and Hormones and Opiates & Controlled Substances. The company has production sites located in France, the United Kingdom, Germany, Italy and Hungary.
EUROAPI SASU
15, rue Traversiere
Paris ILE-DE-FRANCE FR
Employees: 3187
Phone: 33189206200
The current stock price of EAPI.PA is 2.962 EUR. The price increased by 3.57% in the last trading session.
The exchange symbol of EUROAPI SASU is EAPI and it is listed on the Euronext Paris - Matif exchange.
EAPI.PA stock is listed on the Euronext Paris - Matif exchange.
13 analysts have analysed EAPI.PA and the average price target is 2.86 EUR. This implies a price decrease of -3.41% is expected in the next year compared to the current price of 2.962. Check the EUROAPI SASU stock analysts ratings, price target forecast and up-and down grades for more detailed information.
EUROAPI SASU (EAPI.PA) has a market capitalization of 283.14M EUR. This makes EAPI.PA a Micro Cap stock.
EUROAPI SASU (EAPI.PA) currently has 3187 employees.
EUROAPI SASU (EAPI.PA) has a support level at 2.78 and a resistance level at 2.93. Check the full technical report for a detailed analysis of EAPI.PA support and resistance levels.
The Revenue of EUROAPI SASU (EAPI.PA) is expected to decline by -2.6% in the next year. Check the estimates tab for more information on the EAPI.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
EAPI.PA does not pay a dividend.
EUROAPI SASU (EAPI.PA) will report earnings on 2026-03-03, after the market close.
EUROAPI SASU (EAPI.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.31).
ChartMill assigns a fundamental rating of 3 / 10 to EAPI.PA. EAPI.PA may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months EAPI.PA reported a non-GAAP Earnings per Share(EPS) of -1.31. The EPS increased by 56.83% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -8.62% | ||
ROE | -13.04% | ||
Debt/Equity | 0.07 |
13 analysts have analysed EAPI.PA and the average price target is 2.86 EUR. This implies a price decrease of -3.41% is expected in the next year compared to the current price of 2.962.
For the next year, analysts expect an EPS growth of 62.94% and a revenue growth -2.6% for EAPI.PA